Ordering from the Americas?Switch to the US store
Account
←Back to the table|The table›Muscle Growth›CJC-1295 no DAC
Muscle GrowthCj
CJC-1295 no DAC vial, 5 mg
vial · 5 mg
◉Lot numberedLot on every label
✓Research use onlyIn vitro only
❄Cold-chain shippingInsulated, tracked

CJC-1295 no DAC

Coming soonMod GRF 1-29

29-residue amidated analogue of growth hormone-releasing hormone, also written modified GRF (1-29), with four amino acid substitutions relative to sermorelin. Researchers study GHRH receptor pharmacology and analogue design.

Select format
Select content
Choose quantity · save more
Need solvent? Add extra below
€49.00

Coming soon

SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2CAS863288-34-0FormulaC152H252N44O42AliasesMod GRF 1-29, CJC-1295 without DAC, CJC-1295FormatvialContent5 mg

Supplied as a single-chamber lyophilized vial with a colour-coded cap (Muscle Growth).

Questions about CJC-1295 no DAC

How much published research is there on CJC-1295 no DAC?

The research library's PubMed search for CJC-1295 no DAC returned 34 records on 5 October 2026, 10 of them reviews. The library lists 6 studies chosen for what they measured. ClinicalTrials.gov lists 1 registered studies naming CJC-1295 no DAC, 1 of them sponsored by ConjuChem (checked 5 October 2026).

Is CJC-1295 no DAC an approved medicine?

No centrally authorised medicine containing CJC-1295 no DAC is listed in the EMA medicines database (checked 5 October 2026), and the research material we supply is not a medicine. It is supplied for in-vitro laboratory research only, not for human or veterinary use.

Do the published CJC-1295 papers apply to CJC-1295 without DAC?

Mostly not directly. The clinical papers on CJC-1295 describe the albumin-binding (DAC) form, whose half-life is reported as 8 days (PMIDs 16352683 and 17018654). The peptide listed here is the unconjugated form, also written modified GRF (1-29).

How does CJC-1295 no DAC differ from Sermorelin?

CJC-1295 without DAC and sermorelin are both 29-residue amidated analogues of the N-terminal fragment of growth hormone-releasing hormone. They differ at four positions.

How is the identity of CJC-1295 no DAC confirmed on a certificate?

A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 3367.9 Da listed on this page. The research library's guide to reading a certificate explains each field.

What other names is CJC-1295 no DAC published under?

CJC-1295 no DAC is also written Mod GRF 1-29, CJC-1295 without DAC and CJC-1295. The catalog lists it under the name CJC-1295 no DAC.

Is this product for human use?

No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.

Where can I find shipping information?

Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.

Often studied with

IpamorelinMuscle Growth
€39.00/ 5 mg
TesamorelinMuscle Growth
€44.90/ 5 mg
SermorelinMuscle Growth
€49.00/ 5 mg
← Back to the tableMore in Muscle Growth →

For research use only. Not for human or veterinary use.

What is CJC-1295 no DAC?

CJC-1295 without DAC, also written modified GRF (1-29), is a 29-residue amidated analogue of growth hormone-releasing hormone with four amino acid substitutions relative to sermorelin. Most published pharmacology concerns the albumin-binding (DAC) form, not this unconjugated peptide. We supply CJC-1295 no DAC as a lyophilized vial for in-vitro laboratory research only.

What are the chemical identifiers of CJC-1295 no DAC?

CJC-1295 no DAC has the molecular formula C152H252N44O42, an average molecular weight of 3367.9 Da and CAS number 863288-34-0.

Chemistry checked against PubChem (CID 56841945), 5 October 2026; full chemistry record in the research library.

What does published research on CJC-1295 no DAC cover?

A PubMed search for CJC-1295 no DAC returned 34 records on 5 October 2026, 10 of them reviews. Our research library lists 6 of these studies, chosen for what they measured.

  • Growth hormone-releasing hormone acts at a pituitary G-protein-coupled receptor that was cloned in 1992; reviews describe its signal transduction and physiology. (Mayo, Mol Endocrinol, 1992; PMID 1333056; Mayo et al., Ann N Y Acad Sci, 1996; PMID 8993403)
  • Albumin bioconjugates of GRF(1-29) were made and tested for stability against peptidase degradation and for activity at the GRF receptor. (Jetté et al., Endocrinology, 2005; PMID 15817669)

Mechanism, every cited study and the regulator records are on the CJC-1295 no DAC page of the research library. Papers are listed by what they measured, not as evidence of any use.

How is CJC-1295 no DAC supplied and stored?

CJC-1295 no DAC is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.

What is the regulatory status of CJC-1295 no DAC?

The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming CJC-1295 no DAC (searched as CJC-1295) as an active substance. National authorisations are not in that dataset.

No SmPC, PIL or PAR document in MHRA Products matches the exact name (checked 5 October 2026).

The WADA 2026 Prohibited List names this substance under S2.2.4. A WADA entry is a sporting rule, not a statement about legality outside sport.

A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.

Which related research pages and compounds are listed?

Related compounds in the catalog: